OOIR: Observatory of International Research

Papers

(The median citation count of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Issue Information	2151
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	1703
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	871
	814
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	534
	384
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	283
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	275
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India	260
	178
Reframing motherhood in dementia research: A call for action	173
	172
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study	165
Why the cognitive “fountain of youth” may be upstream: Pathways to dementia risk and resilience through social connectedness	162
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study	161
Alzheimer's disease‐induced phagocytic microglia express a specific profile of coding and non‐coding RNAs	157
Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation	147
Putting participants and study partners FIRST when clinical trials end early	145
Entorhinal vessel density correlates with phosphorylated tau and TDP‐43 pathology	136
Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease	135
	130
	129
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab	124
ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods	120
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	118

Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts	118
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern	117
HbA_1c variability associated with dementia risk in people with type 2 diabetes	103
FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness	102
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study	98
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	94
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC	92
Characterizing molecular and synaptic signatures in mouse models of late‐onset Alzheimer's disease independent of amyloid and tau pathology	91
Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?	91
Dementias Platform UK: Bringing genetics into life	83
Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease	77
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years	75
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	75
Issue Information	74
Ethnic Disparities in Clinical Presentation of Patients with Early‐Onset Alzheimer’s Disease	72
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	72
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	72
The relationship between cortical grey to white matter signal contrast (GWC) and tau pathology in atypical AD	69
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	69
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	68
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	67
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	67
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	65
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	65
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	64
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	64
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study	64
Is QEEG an effective biomarker in predicting cognitive decline?	61
The association of gait velocity and cognitive performance in a sample of older Chinese Americans: A pilot study	61
Prediction of amyloid‐beta accumulating normal cognitive elderly	60
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	60
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	60
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study	59
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	59
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	59
The impact of the COVID‐19 pandemic on cognitive health	58
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	58
Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood‐based biomarker discovery	58
The troubles and needs of family caregivers of older adults with moderate to severe dementia	57
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	57
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	55
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	54
CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD	54
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	54
Rural/Urban Disparities in PQIs Among Patients with ADRD – Evidence of Hospital‐based HIT and Enabling Services	53
Associations of sleep disturbances with cognitive function and plasma Alzheimer’s biomarkers in Chinese rural‐dwelling older adults: A population‐based study	53
Optimized ACI‐24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and Pyroglutamate Abeta, key pathological species of Alzheimer’s disease (AD)	52
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network	52
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	51
Testamentary Capacity Assessment Tool (TCAT): An update report	51

Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	50
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	50
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	50
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	50
DETECT‐AD (Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer’s Disease): A simulated anti‐amyloid clinical trial using digital biomarkers as primary outcome measures	49
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	49
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	49
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	48
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	48
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	48
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	47
Theta‐Gamma Phase‐Amplitude Coupling Deficit in Streptozotocin AD Rat Model	47
Persistent pain is associated with lower locus coeruleus integrity in older adults	47
Networking analysis for neuroimaging and genetic markers in Alzheimer's disease	47
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis	46
Generative Adversarial Network‐Enhanced Ultra‐low‐dose [18F]‐PI‐2620 Tau PET/MR Imaging	46
LANGaware: Introducing the right solution for the early detection of neurodegenerative and psychiatric diseases	46
CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease	46
Improved functional connectivity after a 6‐month ketogenic supplementation in mild cognitive impairment	45
The association between diabetes and Alzheimer’s disease pathophysiology	44
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	44
The influence of amyloid on tau deposition in clinically obese participants	44
Subjective Social Status, Brain Health, and Cognitive Reserve Across Race/Ethnicity and Sex/Gender	44
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	44
Associations between imaging biomarkers and sleep quality in the U.S. POINTER study baseline cohort	44
Assessing attitudes and beliefs of dementia risk and prevention in middle‐aged adults	44
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)	44
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	44
The association between cardiorespiratory fitness and resting‐state functional connectivity in adults with Down syndrome	44
A machine learning approach to predict amyloid and tau positivity using clinical features	43
Issue Information	43
Program of intensive support in emergency departments for care partners of cognitively impaired patients: A randomized controlled trial	43
Prevalence of Dementia among Malawian adults with HIV and without HIV: A Medical Record Review	43
A cross‐sectional analysis of Alzheimer’s disease plasma biomarkers and gait variables in cognitively normal older adults	43
Genetic Screening of Frontotemporal Dementia Patients from a Memory Clinic in Argentina	43
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	43
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease	42
Elderly Role Performance Occupational Therapy	42
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	41
Bibliographic Analysis of Aging Anxiety and Lifestyle	41
Improving Early Detection of White Matter Degeneration in Aging and Dementia along the AD continuum	41
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	41
Comparison of remote and in‐person digital speech‐based measures of cognition	41
Experiences of People Living with Dementia and their Care Partners in Participating in Outdoor Activities	41
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	40
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	40
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	40
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	40
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	40
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	40
Cerebellar‐cortical functional connectivity is associated with Alzheimer’s disease pathology and cerebellar atrophy	39
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	39
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	39
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	39
Cerebral perfusion and amyloidosis in the oldest‐old	39
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	39
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	39
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	39
Using an integrated multi‐omics approach to predict dementia: Explainable variational autoencoder (E‐VAE) classifier model	39
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	38
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	38
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	38
What attributes have been included in discrete choice experiments related to health technologies used in the early detection, diagnosis and treatment of neurodegenerative conditions? A systematic lite	38
Association between ¹⁸F – FDG uptake and global cognitive performance in individuals at risk of dementia	38
Assessment of apathy‐like behaviour in transgenic mouse models of neurodegenerative diseases	38
Impact of left censoring on longitudinal analyses of dementia using electronic health record data	37
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	37
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	37
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	37
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	37
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	37
Longitudinal white matter hyperintensities in Down’s syndrome	36
Interneuron hyperexcitability in an APP/PS1 mouse model of Alzheimer’s disease	36
Single‐nucleus RNAseq‐derived pseudo‐temporal modeling of neurodegeneration in astrocytes of older brains	36
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	36
Behavioral reaction to amyloid beta status disclosure	36
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	36
Seizures exacerbate tau spread in the 5XFAD mouse model	36
Bridging the Gap: The Global CEOi Collaborative Workgroup for Adoption of Alzheimer’s disease Blood‐Based Biomarkers in Clinical Practice	35
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	35

Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	35
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	35
Developing a preference‐based quality of life for people living with dementia in Vietnam	35
Advanced measures of cortical microstructural change and associations with cognitive and blood‐based biomarkers in autosomal dominant Alzheimer’s disease	34
Mechanisms Mediating the Anti‐inflammatory Effects of Eicosapentaenoic Acid in the APPswePS1dE9 Alzheimer's Mouse Model	34
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	34
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	34
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	34
Assessment of ccf‐Mitochondrial DNA Damage in Cognitive Impairment via NGS: Health Disparities in Mexican Americans	34
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	34
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	34
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	34
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	34
An international core outcome set for primary progressive aphasia (COS‐PPA): Consensus‐based recommendations for communication interventions across research and clinical settings	33
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	33
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	33
Clinically relevant monitoring of long‐term night‐time behaviour and physiology from the homes of people living with dementia	33
Re‐evaluation of the genetic role of a rare APOE variant (L28P; APOE^4Pittsburgh*) in late‐onset Alzheimer disease	32
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers	32
Longitudinal associations between racial discrimination and brain aging among black older adults	32
Tracing individual trajectory of longitudinal tau spreading in deep latent space	32
Fish intake and MRI burden of cerebrovascular disease in older adults	32
Smartphone ownership and usage in Chinese‐ and English‐speaking older adults	32
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	32
Associations of hippocampal cholinergic receptor binding and subcortical cerebrovascular disease with whole brain volume in cognitive aging and AD	32
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	32
Combination of baicalein and trans‐chalcone synergistically reduces amyloid beta and its toxicity in yeast	32
Racial‐ethnic differences in baseline and longitudinal change in neuropsychological test scores in the NACC Uniform Data Set 3.0	31
Autophagy and lysosomal defects in cells expressing disease‐associated tau	31
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	31
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	31
Circulating extracellular vesicles of neurovascular origin are elevated in women with severe preeclampsia years after their affected pregnancies	31
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	31
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	31
Automating the verbal paired associates test to assess memory remotely and at scale	31
Memory decline is not normal, healthy brain aging	31
The dementia policies in Australia relating to the COVID‐19 pandemic	31
Concordance and diagnostic accuracy between Innotest and two fully automated platforms: Elecsys and Lumipulse	31
Impairment of auditory integration in subjective cognitive decline, amnestic mild cognitive impairment, and Alzheimer’s disease	30
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum	30
The chauffeur who banged cars happily: an interesting case of rapidly progressive strategic infarct dementia	30
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	30
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	30
Sex differences in functional network topological measures in the APP‐PS1 mouse model of amyloidosis	30
Trajectories of self‐rated concerns in individuals developing cognitive decline	30
Heart failure associations with cerebral structure: combined analysis from the Multi‐Ethnic Study of Atherosclerosis (MESA) and the SECRET‐II trial of heart failure with preserved ejection fraction	30
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	30
Neuropathology of a patient with AD treated with low doses of verubecestat	30
Neuropathological features of antemortem atrophy‐based subtypes of Alzheimer’s disease	30
Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults	30
Spatiotemporal transcriptomic characterization of an amyloid mouse model of Alzheimer’s disease	29
Multi‐center study reveals impairment of cortical tissue oxygenation during rising blood CO2 tension in MCI and AD patients	29
Validation of Mitochondria‐Targeted AD Therapeutics in Human Neuronal Cells	29
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	29
Despite heightened risk of cognitive decline, no evidence of local atrophy in people with subjective cognitive decline compared to normal controls in ADNI	29
Human postmortem studies as a driver of biomarker development	29
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	29
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	29
Prevalence, incidence and associations of dementia with cardiovascular risk factors in the Latin American and Caribbean population. A population‐based cohort study of 10/66 Dementia Research Group	29
Association of life‐course traumatic brain injury with the risk of dementia: a nationwide twin study	29
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	28
On the role of neuropsychiatric symptoms as markers for Alzheimer´s disease in an era of disease modifying treatments	28
Meaning from tragedy: exploring attitudes toward dementia patient participation in research	28
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	28
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	28
Cross‐cultural properties of the Cross‐cultural Dementia Screening test and the European Cross‐Cultural Neuropsychological Test Battery	28
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	28
Biomarker driven enrichment strategies for tau pathology in AD clinical trials	28
Anti‐ulcer drug teprenone clinical trial	28
Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling	28
Applications of PRESS‐MRS, MEGA‐PRESS, and pCASL to evaluate treatment effect of Kami Guibi‐tang on amnestic MCI	27
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	27
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	27
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	27
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	27
Emergence of visual artistic creativity in frontotemporal dementia	27
Relationship between amyloid and tau levels and its impact on tau spreading	27
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	26
A simple, automated, speech‐based and AI‐enhanced screener for mild cognitive impairment and amyloid beta positivity	26
Identifying individuals with non‐AD co‐pathologies: A precision medicine approach to clinical trials in sporadic AD	26
Association Between Neuropsychiatric Symptoms and Blood‐Based Autoantibody Biomarkers	26
Myeloid Differentiation Factor 2 Inhibition Protects Against Doxorubicin‐induced Microglial Activation and Senescence	26
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study	26
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	26
In vitro activity of polyphenol‐rich extract of sorghum relevant to treatment of Alzheimer’s disease	26
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	25
Predicting Transitions from Mild Cognitive Impairment to Dementia within 5‐years	25
Cognitive health risks posed by social isolation and loneliness in older Korean Americans	25
Characterization of behavioral changes, MRI brain volumetry and brain metabolic profile of 5xFAD mouse model of Alzheimer’s disease	25
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	25
Characterizing progressive speech changes in prodromal‐to‐mild Alzheimer’s disease using natural language processing	25
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	25
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	25
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	25
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	25